About this trial
The study will be implemented as a retrospective, noninterventional medical record review of patients from routine practice settings who have been diagnosed with a/m non-squamous NSCLC with or without AGA and received at least 1 line of systemic treatment after failing PTC between January 2017 and December 2024.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Confirmed diagnosis of patients with non-squamous NSCLC stage IIIB/IIIC not eligible for curative-intent therapies or stage IV/M1 (a/m NSCLC) with or without actionable genomic mutations (i.e., EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping, RET, HER-2)
Aged at least 18 years at first diagnosis of a/m NSCLC
For the AGA subgroup, having received platinum-based chemotherapy, having received at least one target approved therapy.
For the non_AGA subgroup,should have received either sequential or concurrent use of ICI and PTC)
Disqualifiers
Patients with evidence of other primary malignancies (apart from basal cell carcinoma and melanoma) within 1 year prior to the index date will be excluded from both the study cohorts.
Patients who participated in an investigational clinical trial for the treatment of any cancer, including NSCLC, or any early access program from 2018 onward.
Trial population
The study population will consist of sequential adult patients in study sites with a diagnosis of IIIB/IIIC/IV non-squamous NSCLC with or without AGA and received at least 1 line of treatment after failing PTC for a/m NSCLC with a start date between January 2017 and December 2024.
Trial design
Cohort
Retrospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Describe the patient population and treatment patterns
Description of patient population and treatment patterns: tumor histology, mutation and PD-L1 status, disease stage at diagnosis
Describe the patient population and treatment patterns
Description of patient population and treatment patterns: disease stage at diagnosis
Describe the patient population and treatment patterns
Description of patient population and treatment patterns: smoking status
Describe the patient population and treatment patterns
Description of patient population and treatment patterns: age
Sponsors and contacts
Click on the lead sponsor to view all of their trials.